1422772-78-8

Basic information

• Product Name: 2-bromo-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid
• Synonyms: 2-bromo-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid
• CAS NO: 1422772-78-8
• Molecular Formula: C7H4BrN3O2
• Molecular Weight: 242.04
• Mol File: 1422772-78-8.mol

Chemical Properties

• Appearance: /
• Density: 2.068±0.06 g/cm3(Predicted)
• PKA: -3.11±0.30(Predicted)
• CAS DataBase Reference: 2-bromo-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid(1422772-78-8)
• EPA Substance Registry System: 2-bromo-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid(1422772-78-8)

Safety Data

• Hazardous Substances Data: 1422772-78-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-bromo-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid is used as a synthetic intermediate for the preparation of various complex organic molecules. Its unique structure and functional groups make it a valuable building block in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Medicinal Chemistry:
2-bromo-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid is used as a lead compound in the development of new drugs. Its potential biological activities, such as antimicrobial, antiviral, or anticancer properties, may be exploited to design and optimize therapeutic agents for various diseases and conditions.
Used in Pharmaceutical Industry:
2-bromo-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid is used as a potential therapeutic agent for the treatment of various diseases. Its chemical structure and properties may contribute to its efficacy and selectivity in targeting specific biological pathways or receptors, making it a promising candidate for further research and development in the pharmaceutical field.

Upstream product

• 875781-41-2 5-bromo-3-((trimethylsilyl)ethynyl)pyrazine-2-amine 
• 1185428-32-3 2-bromo-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde 
• 1334674-88-2 (2-bromo-5H-pyrrolo[2,3-b]pyrazin-7-yl)-methanol 
• 1334674-87-1 (2-bromo-5-hydroxymethyl-5H-pyrrolo[2,3-b]pyrazin-7-yl)-methanol 
• 875781-43-4 2-bromo-5H-pyrrolo[2,3-b]pyrazine 

Downstream Products

• 1422772-98-2 2-bromo-N-(1-(tert-butyldimethylsilyloxy)-2-methylpropan-2-yl)-5-trityl-5H-pyrrolo[3,2-b]pyrazine-7-carboxamide 
• 1426425-53-7 N-(1-(tert-butyldimethylsilyloxy)-2-methylpropan-2-yl)-2-(5-(difluoromethoxy)-1-(3-(dimethylamino)propyl)-1H-indazol-3-yl)-5-trityl-5H-pyrrolo[3,2-b]pyrazine-7-carboxamide 
• 1422773-00-9 2-bromo-N-tert-butyl-5-trityl-5H-pyrrolo[3,2-b]pyrazine-7-carboxamide 
• 1422773-01-0 N-tert-butyl 2-(5-(difluoromethoxy)-1H-indazol-3-yl)-5-trityl-5H-pyrrolo[3,2-b]pyrazine-7-carboxamide 
• 1426425-65-1 N-tertbutyl 2-(5-(difluoromethoxy)-1-(3-(methylsulfonyl)propyl)-1H-indazol-3-yl)-5-trityl-5H-pyrrolo[3,2-b]pyrazine-7-carboxamide 
• 1426425-62-8 N-tertbutyl-2-(5-(difluoromethoxy)-1-(2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-1H-indazol-3-yl)-5-trityl-5H-pyrrolo[3,2-b]pyrazine-7-carboxamide 
• 1422773-04-3 N-tert-butyl-2-(6-fluoro-1H-indazol-3-yl)-5-trityl-5H-pyrrolo[3,2-b]pyrazine-7-carboxamide 
• 1426425-83-3 N-tert-butyl-2-(6-fluoro-1-(3-(methylsulfonyl)propyl)-1H-indazol-3-yl)-5-trityl-5H-pyrrolo[3,2-b]pyrazine-7-carboxamide 
• 1422773-06-5 N-(1-(tert-butyldimethylsilyloxy)-2-methylpropan-2-yl)-2-(6-fluoro-1H-indazol-3-yl)-5-trityl-5H-pyrrolo[3,2-b]pyrazine-7-carboxamide 
• 1426425-94-6 N-(1-(tertbutyldimethylsilyloxy)-2-methylpropan-2-yl)-2-(6-fluoro-1-(3-oxobutyl)-1H-indazol-3-yl)-5-trityl-5H-pyrrolo[3,2-b]pyrazine-7-carboxamide 
• 1426425-95-7 N-(1-(tert-butyldimethylsilyloxy)-2-methylpropan-2-yl)-2-(6-fluoro-1-(3-hydroxybutyl)-1H-indazol-3-yl)-5-trityl-5H-pyrrolo[3,2-b]pyrazine-7-carboxamide 
• 1426425-82-2 N-tert-butyl-2-(1-(2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl)-6-fluoro-1H-indazol-3-yl)-5-trityl-5H-pyrrolo[3,2-b]pyrazine-7-carboxamide 
• 1426425-97-9 N-(1-(tertbutyldimethylsilyloxy)-2-methylpropan-2-yl)-2-(6-fluoro-1-(3-(methylsulfonyl)propyl)-1Hindazol-3-yl)-5-trityl-5H-pyrrolo[3,2-b]pyrazine-7-carboxamide 

Relevant articles and documents

PYRROLOPYRIMIDINE ITK INHIBITORS

Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structures of Formulas (I)-(IV): wherein the R groups, m, n, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.

Heteroaromatic compound and application thereof to drug

The invention discloses a heteroaromatic compound and application thereof to drug. In particular, the invention provides a heteroaromatic compound or stereoisomers thereof, geometric isomers, tautomers, racemates, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, and a pharmaceutical composition comprising the compound provided by the invention. The invention also discloses application of the compound provided by the invention or the pharmaceutical composition thereofto preparation of a medicine for reatment of autoimmune diseases or proliferative diseases.

PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL, PYRROLO[2,3-B]PYRIDINYL ACRYLAMIDES AND EPOXIDES THEREOF

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3- b]pyrazinyl,and pyrrolo[2,3-b]pyridinyl acrylamides, epoxides,and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention

PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYR-ROLO[2,3-D]PYRIDINYL ACRYLAMIDES

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

PYRROLOPYRAZINE KINASE INHIBITORS

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors

We describe the discovery of several pyrrolopyrazines as potent and selective Syk inhibitors and the efforts that eventually led to the desired improvements in physicochemical properties and human whole blood potencies. Ultimately, our mouse model revealed unexpected toxicity that precluded us from further advancing this series.